Table 2.
Trials design data.
| Study Type | Number | Percentage | ||
|---|---|---|---|---|
| Interventional | Total | 943 | 100% | |
| Number of Arms | ||||
| 1 | 161 | 17.1% | ||
| 2 | 622 | 66.0% | ||
| 3 | 83 | 8.8% | ||
| 4 | 47 | 5.0% | ||
| > 4 | 29 | 3.1% | ||
| NA | 1 | 0.1% | ||
| Allocation | ||||
| Randomized | 720 | 76.4% | ||
| Non-Randomized | 78 | 8.3% | ||
| NA | 145 | 15.4% | ||
| Intervention Model | ||||
| Single Group Assignment | 160 | 17.0% | ||
| Parallel Assignment | 717 | 76.0% | ||
| Sequential Assignment | 33 | 3.5% | ||
| Factorial Assignment | 12 | 1.3% | ||
| Crossover Assignment | 21 | 2.2% | ||
| Masking (Blinding) | ||||
| Open Label | 530 | 56.2% | ||
| Single | 102 | 10.8% | ||
| Double | 109 | 11.6% | ||
| Triple | 66 | 7.0% | ||
| Quadruple | 136 | 14.4% | ||
| Primary Purpose | ||||
| Treatment | 714 | 75.7% | ||
| Prevention | 124 | 13.1% | ||
| Others | 105 | 11.1% | ||
| Phases | ||||
| Early Phase 1 | 18 | 1.9% | ||
| Phase 1 | 47 | 5.0% | ||
| Phase 1|Phase 2 | 54 | 5.7% | ||
| Phase 2 | 265 | 28.1% | ||
| Phase 2|Phase 3 | 76 | 8.1% | ||
| Phase 3 | 174 | 18.5% | ||
| Phase 4 | 56 | 5.9% | ||
| NA | 253 | 26.8% | ||
| Observational | Total | 600 | 100% | |
| Observational Model | ||||
| Case-Only | 52 | 8.7% | ||
| Case-Control | 74 | 12.3% | ||
| Cohort | 376 | 62.7% | ||
| Other | 98 | 16.3% | ||
| Time Perspective | ||||
| Retrospective | 100 | 16.7% | ||
| Prospective | 377 | 62.8% | ||
| Cross-Sectional | 67 | 11.2% | ||
| Other | 56 | 9.3% | ||
| Diagnostic Test | Total | 145 | 100% | |
| Imaging exams | 32 | 22.1% | ||
| nucleic acid detection | 36 | 24.8% | ||
| IgM/IgG | 15 | 10.3% | ||
| Other | 62 | 42.8% | ||
NA, Not available.